Prospective therapeutics for age-related macular degeneration

Bibliography

• GASS JDM: Diseases causing choroidal exudative and hemorrhagic localized (Disciform) detachment of the retina and retinal pigment epithelium. In: Stereoscopic Atlas of Macular Diseases. Mosby, St. Louis, Missouri, USA (1997) 1:49–286.
   Google Scholar
• GREEN WR: Pathology of the macula. In: Ophthalmic Pathology. Spencer WH (Ed.), WB Sounders Company, Philadelphia, Pennsylvania, USA (1996) 2:973–1107.
   Google Scholar
• SARKS SH, SARKS JP: Age-related macular degeneration: atrophic form. In: Medical Retina. Schachat AP, Murphy RB (Eds.), Mosby, St. Louis, Missouri, USA (1994) 2:1071–1102.
   Google Scholar
• ELMAN MJ, FINE SL: Exudative age-related macular degeneration. In: Medical Retina. Schachat AP, Murphy RB (Eds.), Mosby, St. Louis, Missouri, USA (1994) 2:1103–1141.
   Google Scholar
• ZARBIN MA: Age-related macular degeneration: review of pathogenesis. Eur. J. Ophthalmol. (1998) 8:199–206.
   PubMed Web of Science ®Google Scholar
• O'SHEA JG: Age-related macular degeneration: a leading cause of blindness. Med. J. Australia (1996) 165:561–564.
   PubMedGoogle Scholar
• BIRD AC: Pathogenesis of retinal pigment epithelialdetachment in the elderly: the relevance of Bruch's membrane change. Eye (1991) 5:1–12.
   PubMed Web of Science ®Google Scholar
• CURCIO CA, MILLICAN CL: Basal linear deposit and large drusen are specific for early age-related maculopathy. Arch. Ophthalmol (1999) 117:329–339.
   PubMedGoogle Scholar
• PETRUSKHIN K, KOISTI MJ, BACALL B et al.: Identifica-tion of the gene responsible for Best macular dystrophy. Nature Genet. (1998) 19:241–247.
   PubMedGoogle Scholar
• WEBER BHF, VOGT G, PRUETT RC, STOHR H, FELBOR U: Mutations in the tissue inhibitor of metalloproteinases-3 (TIMP3) in patients with Sorby's fundus dystrophy. Nature Genet. (1994) 8:352–356.
   PubMedGoogle Scholar
• DRYJA TP: The best excitement in age-related macular degeneration. Arch. Ophthalmol. (1999) 117:108–109.
   PubMedGoogle Scholar
• ••Presents the current perspective about the moleculargenetics of AMD and related diseases.
   Google Scholar
• BRESSLER NM, SILVA JC, BRESSLER SB, FINE SL, GREEN WR: Clinicopathologic correlation of drusen and retinal pigment epithelial abnormalities in age related macular degeneration. Retina (1994) 14:130–142.
   PubMed Web of Science ®Google Scholar
• ABDELSALAM A, DEL PRIORE L, ZARBIN MA: Drusen in age-related macular degeneration: pathogenesis, natural course, and laser photocoagulation-induced regression. Sun'. Ophthalmol. (1999) 44:1–29.
   PubMed Web of Science ®Google Scholar
• LEIBOWITZ HM, KRUEGER DE, MAUNDER LR et al.: The Framingham Eye Study Monograph: IV Macular degeneration. Sun'. Ophthalmol. (1980) 24:428–457.
   Google Scholar
• KLEIN R, KLEIN BEK, LINTON KLP: Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology (1992) 99:933–943.
   PubMedGoogle Scholar
• BRESSLER NM, BRESSLER SB, WEST SK, FINE SL, TAYLOR HR: The grading and prevalence of macular degenera-tion in the Chesapeake Bay Watermen Study. Arch. Ophthalmol (1989) 107:847–852.
   PubMed Web of Science ®Google Scholar
• EYE DISEASE CASE-CONTROL STUDY GROUP: Risk factors for neovascular age-related macular degenera-tion. Arch. Ophthalmol (1992) 110:1701–1708.
   PubMedGoogle Scholar
• FERRIS FL: Senile macular degeneration, review ofepidemiologic features. Am. J. Epidemiol. (1983) 118:132–151.
   PubMed Web of Science ®Google Scholar
• MACULAR PHOTOCOAGULATION STUDY GROUP: Risk factors for choroidal neovascularization in the second eye of patients with juxtafoveal or subfoveal choroidal neovascularization secondary to age-related macular degeneration. Arch. Ophthalmol. (1997) 115:741–747.
   PubMedGoogle Scholar
• •Contains the references to the numerous reports of the Macular Photocoagulation Study.
   Google Scholar
• JOFFE L: The medical and surgical management of age-related macular degeneration. Int. Ophthalmol. Clin. (1996) 36:99–116.
   PubMedGoogle Scholar
• CHONG NHV, BIRD AC: Alternative therapies in exudative age-related macular degeneration. Br. J. Ophthalmol (1998) 82:1441–1443.
   PubMedGoogle Scholar
• CIULLA TA, DANIS RP, HARRIS A: Age-related macular degeneration: a review of experimental treatments. Sun'. Ophthalmol (1998) 43:134–146.
   PubMed Web of Science ®Google Scholar
• PECE A, INTROINI U, BOLOGNESI G, BRANCATO R: Indocyanine green angiography in age-related macular degeneration with occult neovascularization. Ophthalmologica (1998) 212:295–300.
   PubMedGoogle Scholar
• MABERLY DA, CRUESS AF: Indocyanine green angiography: an evaluation of image enhancement for the identification of occult choroidal neovascular membranes. Retina (1999) 19:37–44.
   PubMedGoogle Scholar
• HUBBARD G, ALTOMARE F, KAUSHAL S, JOSEPH NM, HOLEKAML MA: Foveal translocation with and without removal of choroidal neovascular membranes. Invest. Ophthalmol. Vis. Sci. (1999) 40:S207.
   Google Scholar
• DE JUAN E, LOEWENSTEIN A, BRESSLER NM: Transloca-tion of the retina for management of subfoveal choroidal neovascularization II: a preliminary report in humans. Am. J. Ophthalmol (1998) 125:635–646.
   PubMed Web of Science ®Google Scholar
• KAPLAN HJ, TEZEL TH, DEL PRIORE LV: Retinal pigment epithelial transplantation in age-related macular degeneration. Retina (1998) 18:99–102.
   PubMedGoogle Scholar
• DOUGHERTY TJ, GOMER CJ, HENDERSON BW et al: Photodynamic therapy. J. Natl. Cancer Inst. (1998) 90:889–905.
   PubMed Web of Science ®Google Scholar
• OCHSNER M: Photodynamic therapy: the clinical perspective. Review on applications for control of diverse tumorous and non-tumorous diseases. Arzneimittelforschung (1997) 47:1185–1194.
   PubMedGoogle Scholar
• OLEINICK NL, EVANS HH: The photobiology of photodynamic therapy: cellular targets and mechanisms. RadiaL Res. (1998) 150:S146–156.
   PubMed Web of Science ®Google Scholar
• MOORE JV, WEST CM, WHITEHURST C: The biology of photodynamic therapy. Phys. Med. Biol. (1997) 42:913–935.
   PubMed Web of Science ®Google Scholar
• MOSHFEGHI DM, PEYMAN GA, MOSHFEGHI AA, KHOOBEHI B, PRIMBS GB, CREAN DH: Ocular vascular thrombosis following tin ethyl etiopurpurin (SnET2) photodynamic therapy: time dependencies. Ophthalmic Surg. Lasers (1998) 29:663–668.
   PubMedGoogle Scholar
• R&D focus. IMS World Publications Ltd. (1999).
   Google Scholar
• MILLER JW, SCHMIDT-ERFURTH U, SICKENBERG M et al: Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration. Results of a single treatment in a Phase I and II study. Arch. Ophthalmol. (1999) 117:1161–1173.
   PubMedGoogle Scholar
• SCHMIDT-ERFURTH U, MILLER JW, SICKENBERG M et al: Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration. Results of retreatments in a Phase I and II study. Arch. Ophthalmol (1999) 117:1177–1187.
   PubMed Web of Science ®Google Scholar
• BLUMENKRANZ MS, WOODBURN K, VERDOONER S: Lutetium texaphyrin angiography: a new method for the evaluation and treatment of retinal and choroidal vascular disorders. Invest. Ophthalmol. Vis. Sci. (1998) 39:S468.
   Google Scholar
• ASHTON P, VIEIRA W, WU M, KASNOPEROVA N, LEM J,MOHAN R: Intravitreal delivery of angiostatic compounds. Invest. Ophthalmol. Vis. Sci. (1998) 39: S431.
   Google Scholar
• NIESMAN MR, TURNER LK, PENN JS: Liposome-fibronectin conjugates for extended release of therapeutic agents within the vitreous. Invest. Ophthalmol Vis. Sci. (1998) 39:S274.
   Google Scholar
• SAKURAI E, OZEKI H, KUNOU N, OGURA Y: Evaluation of polymeric nanospheres as a controlled drug delivery system to the retina and vitreous. Invest. Ophthalmol Vis. Sci. (1999) 40:S83.
   Google Scholar
• VELEZ G, ROBISON MR, DURBIN T, YUAN P, SUNG C, WHITCUP SM: Thalidomide-sustained release devices for choroidal neovascularization; an in vitro analysis. Invest. Ophthalmol Vis. Sci. (1999) 40:S84.
   Google Scholar
• OTHBERG A, KEEP M, BRUNDIN P, LINVALL O: Tirilazad mesylate improves survival of rat and human embryonic mesencephalic neurons in vitro. Exp. Neurol (1997) 147:498–502.
   PubMedGoogle Scholar
• SMITH SL, SCHERCH HM, HALL ED: Protective effects of tirilazad mesylate and metabolite U-89678 against blood-brain barrier damage after subarachnoid hemorrhage and lipid peroxidative neuronal injury. J. Neurosurg. (1996) 84:229–233.
   PubMed Web of Science ®Google Scholar
• JACOT JL, SREDY J: Emerging therapeutics for diabetic retinopathy: potential therapies for the new millen-nium. Emerging Therapeutic Targets (1999) 3:307–335.
   Google Scholar
• ••Reviews in great detail current ocular anti-angiogenic drugsin development.
   Google Scholar
• D'AMORE PA: Mechanisms of retinal and choroidalneovascularization. Invest. Ophthalmol. Vis. Sci. (1994) 35:3974–3979.
   PubMedGoogle Scholar
• FERRARA N, DAVIS-SMITH T: The biology of vascularendothelial growth factor. Endocrine Rev. (1997) 18:4–25.
   PubMed Web of Science ®Google Scholar
• AIELLO LP, AVERY RL, ARRIGG PG et al.: Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. New Engl. J. Med. (1994) 331:1480–1487.
   PubMed Web of Science ®Google Scholar
• NAGASE H, WOESSNER JF: Matrix metalloproteinases. J. Biol. Chem. (1999) 274:21491–21494.
   PubMed Web of Science ®Google Scholar
• HAGMANN WK, LARK MW, BECKER JW: Inhibition ofmatrix metalloproteinases. Ann. Reports Med. Chem. (1996) 31:231–240.
   Google Scholar
• ETZIONI A: Integrins, the glue of life. Lancet (1999)353:341–343.
   PubMedGoogle Scholar
• PHARMACOLOGICAL THERAPY FOR MACULAR DEGENERATION STUDY GROUP: Interferon alpha-2a is ineffective for patients with choroidal neovasculariza-tion secondary to age-related macular degeneration. Results of a prospective, randomized placebo-controlled clinical trial. Arch. Ophthalmol. (1997) 115:865–872.
   PubMedGoogle Scholar
• AUGSBURGER JJ: Radiotherapy and the treatment of age-related macular degeneration. External beam radiation therapy is not effective in the treatment of age-related macular degeneration. Arch. Ophthalmol (1998) 116:1509–1511.
   Google Scholar
• FINGER PT: Radiotherapy and the treatment of age-related macular degeneration. External beam radiation therapy is effective in the treatment of age-related macular degeneration. Arch. Ophthalmol. (1998) 116: 1507–1509.
   Google Scholar